

Evaluating the safety and efficacy of PRG-N-01 in patients with Neurofibromatosis Type 2



NEUROLOGY	Phase 1
Product Type	Small molecule
Indication	Neurofibromatosis Type 2
Target	Oncopathogenic neo-TβR1-RKIP interaction
MoA(Mechanism of Action)	PRG-N-01 suppresses the formation of NF2-related tumors by binding to TβR1 and disrupting the interaction between TβR1 and RKIP
Competitiveness	<ul style="list-style-type: none"> • Unlike existing TβR1 kinase inhibitors, PRG-N-01 does not inhibit the kinase activity of TβR1 • PRG-N-01 does not interfere with TGF-β signaling, which may prevent side effects from long-term administration • PRG-N-01 acts directly on TβR1, so indications may extend to other pathologies involving TβR1 (such as cancer cell metastasis)
Development Stage	Phase 1
Route of Administration	Oral (Once a day, after meals)